{"altmetric_id":2592531,"counts":{"readers":{"mendeley":8,"citeulike":0,"connotea":0},"total":{"posts_count":14},"twitter":{"unique_users_count":14,"unique_users":["Vilya_SCW","jagasquet","evaglezhaba","NatRevClinOncol","andybreathe","irodriguezpenin","ParvathaneniNK","AndrewRowlandRx","GoToPER","aakonc","Marisol_Ucha","Annals_Oncology","DaleYuzuki","TriConference"],"posts_count":14}},"selected_quotes":["RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: meta-analysis","RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer","Cree: Meta-analysis '15 only 20% 'New RAS total' Suggests 'extended RAS' #TRICON","Just published, we've summarised the trial data on the effect of extended RAS mutations on response to mAbs in mCRC"],"citation":{"abstract":"Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral oncogene (KRAS) exon 2 wild-type tumors. Recent evidence has suggested that other RAS mutations (in exons 3 and 4 of KRAS and exons 2, 3 and 4 of a related gene, NRAS) may also be predictive of resistance.","abstract_source":"pubmed","altmetric_jid":"4f6fa4e83cf058f610002280","authors":["M. J. Sorich","M. D. Wiese","A. Rowland","G. Kichenadasse","R. A. McKinnon","C. S. Karapetis","Sorich MJ","Wiese MD","Rowland A","Kichenadasse G","McKinnon RA","Karapetis CS","Sorich, M. J.","Wiese, M. D.","Rowland, A.","Kichenadasse, G.","McKinnon, R. A.","Karapetis, C. S."],"doi":"10.1093\/annonc\/mdu378","endpage":"21","first_seen_on":"2014-08-13T08:03:50+00:00","handle":"11541.2\/119701","handles":["11541.2\/119701"],"issns":["1569-8041","0923-7534"],"issue":"1","journal":"Annals of Oncology","last_mentioned_on":1457469942,"links":["http:\/\/annonc.oxfordjournals.org\/content\/early\/2014\/08\/12\/annonc.mdu378.short?rss=1","http:\/\/annonc.oxfordjournals.org\/content\/early\/2014\/08\/12\/annonc.mdu378.long","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25115304","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25115304?dopt=Abstract","http:\/\/annonc.oxfordjournals.org\/content\/early\/2014\/09\/22\/annonc.mdu378.long","http:\/\/annonc.oxfordjournals.org\/content\/26\/1\/13.full","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25115304?platform=hootsuite","https:\/\/doi.org\/10.1093\/annonc\/mdu378"],"pdf_url":"http:\/\/annonc.oxfordjournals.org\/content\/early\/2014\/08\/12\/annonc.mdu378.full.pdf","pmid":"25115304","pubdate":"2014-08-11T23:00:00+00:00","publisher":"Oxford University Press","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"13","subjects":["neoplasms"],"title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","type":"article","uri":"https:\/\/academic.oup.com\/annonc\/article-lookup\/doi\/10.1093\/annonc\/mdu378","volume":"26","mendeley_url":"http:\/\/www.mendeley.com\/research\/extended-irasi-mutations-antiegfr-monoclonal-antibody-survival-benefit-metastatic-colorectal-cancer"},"altmetric_score":{"score":8.4,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":8.4},"context_for_score":{"all":{"total_number_of_other_articles":8076231,"mean":6.8570644748779,"rank":999323,"this_scored_higher_than_pct":87,"this_scored_higher_than":7075108,"rank_type":"exact","sample_size":8076231,"percentile":87},"similar_age_3m":{"total_number_of_other_articles":182019,"mean":7.7249423463616,"rank":25482,"this_scored_higher_than_pct":85,"this_scored_higher_than":156486,"rank_type":"exact","sample_size":182019,"percentile":85},"this_journal":{"total_number_of_other_articles":3546,"mean":9.5373196050776,"rank":652,"this_scored_higher_than_pct":81,"this_scored_higher_than":2893,"rank_type":"exact","sample_size":3546,"percentile":81},"similar_age_this_journal_3m":{"total_number_of_other_articles":96,"mean":13.570021052632,"rank":21,"this_scored_higher_than_pct":78,"this_scored_higher_than":75,"rank_type":"exact","sample_size":96,"percentile":78}}},"demographics":{"poster_types":{"member_of_the_public":8,"researcher":5,"science_communicator":1},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":1,"Members of the public":7,"Science communicators (journalists, bloggers, editors)":1,"Scientists":5}},"mendeley":{"by_status":{"Researcher":3,"Student  > Ph. D. Student":3,"Student  > Master":1,"Other":1},"by_discipline":{"Medicine and Dentistry":4,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":1,"Biochemistry, Genetics and Molecular Biology":1,"Unspecified":1}}},"geo":{"twitter":{"GB":2,"ES":2,"US":4}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/Vilya_SCW\/status\/506921100518109184","license":"datasift","rt":["NatRevClinOncol"],"citation_ids":[2592531],"posted_on":"2014-09-02T21:46:23+00:00","author":{"name":"Suravi","url":"http:\/\/chatterjeewoolman.wordpress.com","image":"https:\/\/pbs.twimg.com\/profile_images\/757660663087042561\/tQ9I-rOH_normal.jpg","description":"Medical doctor. Past: corporate bioscience. Passion: making a difference. Blog: http:\/\/vilyascw.wordpress.com Also tweet as @a101hacks","id_on_source":"Vilya_SCW","tweeter_id":"514695612","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":618},"tweet_id":"506921100518109184"},{"url":"https:\/\/twitter.com\/jagasquet\/status\/516445231450181632","license":"datasift","citation_ids":[2592531],"posted_on":"2014-09-29T04:31:52+00:00","author":{"name":"Jose Antonio Gasquet","url":"http:\/\/es.linkedin.com\/in\/jagasquet","image":"https:\/\/pbs.twimg.com\/profile_images\/2546173677\/by2macf06eid3l83z0eb_normal.jpeg","description":"Pharmaceutical\/Biotechnology Professional focused on Oncology. \r\nOpinions are my own","id_on_source":"jagasquet","tweeter_id":"633978297","geo":{"lt":41.38879,"ln":2.15899,"country":"ES"},"followers":571},"tweet_id":"516445231450181632"},{"url":"https:\/\/twitter.com\/evaglezhaba\/status\/516459021034065920","license":"datasift","rt":["jagasquet"],"citation_ids":[2592531],"posted_on":"2014-09-29T05:26:40+00:00","author":{"name":"Eva Gonz\u00e1lez-Haba","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000507057917\/e2e872d268f81caeb2e190f07e552e06_normal.jpeg","description":"FARMAC\u00c9UTICA ONCOLOGICA HGU GREGORIO MARA\u00d1ON","id_on_source":"evaglezhaba","tweeter_id":"1262969371","geo":{"lt":null,"ln":null},"followers":580},"tweet_id":"516459021034065920"},{"url":"https:\/\/twitter.com\/NatRevClinOncol\/status\/499466295700488192","license":"datasift","citation_ids":[2592531],"posted_on":"2014-08-13T08:03:39+00:00","author":{"name":"NatureRevClinOncol","url":"http:\/\/www.nature.com\/nrclinonc\/index.html","image":"https:\/\/pbs.twimg.com\/profile_images\/1587954262\/nrclinonc_Twitter_logo_normal.jpg","description":"The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.","id_on_source":"NatRevClinOncol","tweeter_id":"347276297","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":10546},"tweet_id":"499466295700488192"},{"url":"https:\/\/twitter.com\/andybreathe\/status\/500814283081801728","license":"datasift","citation_ids":[2592531],"posted_on":"2014-08-17T01:20:04+00:00","author":{"name":"Andreas-Cl. Hoffmann","url":"http:\/\/www.more-oncology.de\/","image":"https:\/\/pbs.twimg.com\/profile_images\/827830830995234817\/Bbly2akM_normal.jpg","description":"Hematologist, Medical Oncologist, Cancer Researcher, Follow-up Care After Cancer Treatment, Oncology Rehabilitation, tweets and opinions expressed are my own","id_on_source":"andybreathe","tweeter_id":"220780239","geo":{"lt":null,"ln":null},"followers":421},"tweet_id":"500814283081801728"},{"url":"https:\/\/twitter.com\/irodriguezpenin\/status\/515909478454026241","license":"datasift","citation_ids":[2592531],"posted_on":"2014-09-27T17:02:59+00:00","author":{"name":"Isaura R. Pen\u00edn","image":"https:\/\/pbs.twimg.com\/profile_images\/852984789158297600\/im_VK6Ce_normal.jpg","id_on_source":"irodriguezpenin","tweeter_id":"1058366989","geo":{"lt":null,"ln":null},"followers":194},"tweet_id":"515909478454026241"},{"url":"https:\/\/twitter.com\/ParvathaneniNK\/status\/499472906339237888","license":"datasift","rt":["NatRevClinOncol"],"citation_ids":[2592531],"posted_on":"2014-08-13T08:29:55+00:00","author":{"name":"Nanda Parvathaneni","image":"https:\/\/pbs.twimg.com\/profile_images\/730824733772648449\/Pjd2LcYO_normal.jpg","id_on_source":"ParvathaneniNK","tweeter_id":"1660690400","geo":{"lt":null,"ln":null},"followers":39},"tweet_id":"499472906339237888"},{"url":"https:\/\/twitter.com\/AndrewRowlandRx\/status\/499544686940278784","license":"datasift","citation_ids":[2592531],"posted_on":"2014-08-13T13:15:09+00:00","author":{"name":"Andrew Rowland","image":"http:\/\/pbs.twimg.com\/profile_images\/471189404237574144\/Lxct6PRk_normal.jpeg","description":"Lecturer at Flinders Uni. Passionate about improving outcomes for cancer patients, teaching young clinicians and researchers, and being the best dad I can be.","id_on_source":"AndrewRowlandRx","tweeter_id":"2526786644","followers":17},"tweet_id":"499544686940278784"},{"url":"https:\/\/twitter.com\/GoToPER\/status\/500321666770010116","license":"datasift","citation_ids":[2592531],"posted_on":"2014-08-15T16:42:35+00:00","author":{"name":"PER","url":"http:\/\/gotoper.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3438723869\/2416df847bccb4c5ad8da6015ba30370_normal.jpeg","description":"Physicians' Education Resource (PER) specializes in oncology and hematology CME-certified activities. We advance cancer care through professional education.","id_on_source":"GoToPER","tweeter_id":"37703552","geo":{"lt":40.31622,"ln":-74.51376,"country":"US"},"followers":4420},"tweet_id":"500321666770010116"},{"url":"https:\/\/twitter.com\/aakonc\/status\/511536045788110848","license":"datasift","citation_ids":[2592531],"posted_on":"2014-09-15T15:24:31+00:00","author":{"name":"Alok Khorana","url":"https:\/\/scholar.google.com\/citations?user=XgTi-LUAAAAJ&hl=en","image":"https:\/\/pbs.twimg.com\/profile_images\/739900566889979905\/a2zOwTYl_normal.jpg","description":"Hardis Endowd Chair in Onc Rsrch, Prof Med, Vice Chair Taussig Cancer Inst, Dir GI Cancers, @ClevelandClinic. Past Chair @ASCO CPGC. Tweets my own. I have #FCOI","id_on_source":"aakonc","tweeter_id":"433714735","geo":{"lt":41.4995,"ln":-81.69541,"country":"US"},"followers":1359},"tweet_id":"511536045788110848"},{"url":"https:\/\/twitter.com\/Marisol_Ucha\/status\/515925173267365889","license":"datasift","rt":["irodriguezpenin"],"citation_ids":[2592531],"posted_on":"2014-09-27T18:05:21+00:00","author":{"name":"Marisol Ucha","image":"https:\/\/pbs.twimg.com\/profile_images\/426798139014524928\/nFH61igd_normal.jpeg","description":"Farmac\u00e9utica especialista en Farmacia Hospitalaria, apasionada del mar y la lectura","id_on_source":"Marisol_Ucha","tweeter_id":"2308827132","geo":{"lt":42.23282,"ln":-8.72264,"country":"ES"},"followers":227},"tweet_id":"515925173267365889"},{"url":"https:\/\/twitter.com\/Annals_Oncology\/status\/555702253416644610","license":"datasift","citation_ids":[2592531],"posted_on":"2015-01-15T12:25:16+00:00","author":{"name":"Annals of Oncology","url":"https:\/\/academic.oup.com\/annonc","image":"https:\/\/pbs.twimg.com\/profile_images\/816266349819416576\/zAo22kcV_normal.jpg","description":"Medical oncology journal with a specific interest on targeted agents, immune therapies, personalised medicine, molecular pathology, bioinformatics, and more.","id_on_source":"Annals_Oncology","tweeter_id":"44614314","geo":{"lt":null,"ln":null},"followers":16564},"tweet_id":"555702253416644610"},{"url":"http:\/\/twitter.com\/DaleYuzuki\/statuses\/707288827535233024","license":"gnip","citation_ids":[2592531],"posted_on":"2016-03-08T19:36:11+00:00","author":{"name":"\u2697\ufe0f\u270d\ufe0fDale Yuzuki \ud83d\udcbc\ud83c\udfaf","url":"http:\/\/www.yuzuki.org","image":"https:\/\/pbs.twimg.com\/profile_images\/682391233868595200\/5a40iby3_normal.jpg","description":"Marketing professional, next-generation sequencing, clinical genomics. Looking for the next opportunity. http:\/\/yuz.li\/9y Opinions are my own.","id_on_source":"DaleYuzuki","tweeter_id":"514806103","geo":{"lt":39.00039,"ln":-76.74997,"country":"US"},"followers":4849},"tweet_id":"707288827535233024"},{"url":"http:\/\/twitter.com\/TriConference\/statuses\/707306321196883968","license":"gnip","rt":["DaleYuzuki"],"citation_ids":[2592531],"posted_on":"2016-03-08T20:45:42+00:00","author":{"name":"Molecular MedTRI-CON","url":"http:\/\/www.TriConference.com","image":"https:\/\/pbs.twimg.com\/profile_images\/740599101452996608\/XhDrFmGh_normal.jpg","description":"For 20+ years, the #TRICON is the industry\u2019s Preeminent Event on Molecular Medicine, focusing on Drug Discovery, Genomics, Diagnostics & Information Technology","id_on_source":"TriConference","tweeter_id":"18247542","geo":{"lt":37.77493,"ln":-122.41942,"country":"US"},"followers":1170},"tweet_id":"707306321196883968"}]}}